Long term outcome of a patient with relapsed refractory early thymic precursor acute lymphoblastic leukemia treated with daratumumab.

The prognosis of patients with relapsed Early Thymic Precursor acute lymphoblastic leukemia (ETP-ALL) remains poor. Unlike B cell Precursor-ALL (BCP-ALL), there are no approved targeted therapies for ETP-ALL. Recent studies have identified a consistent expression of CD38 on the blasts of patients with T-ALL (both ETP-ALL and non ETP-ALL). Pre-clinical studies indicate that CD38 expression persists on the blasts of T-ALL even after receipt of conventional chemotherapy. These findings make CD38 an attractive targetable surface protein for patients with relapsed refractory T-ALL. We were the first to describe the clinical use of daratumumab in a patient of ETP-ALL, with relapsed disease post allogeneic transplant. We describe here the long term outcome of this patient more than 3 years after starting single agent daratumumab.

[1]  Omar Castaneda Puglianini,et al.  Early precursor T-cell acute lymphoblastic leukemia: current paradigms and evolving concepts , 2020, Therapeutic advances in hematology.

[2]  Neha Singh,et al.  Will Daratumumab be the next game changer in early thymic precursor‐acute lymphoblastic leukaemia? , 2019, British journal of haematology.

[3]  G. Gahrton,et al.  Infectious complications and NK cell depletion following daratumumab treatment of Multiple Myeloma , 2019, PloS one.

[4]  J. Rowe,et al.  Daratumumab in Combination with Vincristine or Nelarabine As Effective Salvage Therapy for Patients with Acute Lymphoblastic Leukemia at High Risk of Relapse , 2018, Blood.

[5]  J. Connors,et al.  Daratumumab for Delayed Red-Cell Engraftment after Allogeneic Transplantation. , 2018, The New England journal of medicine.

[6]  J. Byrd,et al.  Anti-leukemic effects of all-trans retinoic acid in combination with Daratumumab in acute myeloid leukemia , 2018, International immunology.

[7]  J. Rowe,et al.  Daratumumab for relapsed/refractory Philadelphia-positive acute lymphoblastic leukemia , 2018, Haematologica.

[8]  A. Bonda,et al.  Daratumumab at the frontiers of post-transplant refractory T-acute lymphoblastic leukemia—a worthwhile strategy? , 2018, Bone Marrow Transplantation.

[9]  A. Krishnan,et al.  Graft-versus-host disease (GVHD) risk with daratumumab (Dara) therapy post allogeneic transplantation (alloHCT) for multiple myeloma (MM). , 2018 .

[10]  M. Loh,et al.  Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia. , 2018, Blood.

[11]  P. Moreau,et al.  Daratumumab for the treatment of multiple myeloma , 2017, Expert opinion on biological therapy.

[12]  R. Goldsby,et al.  Daratumumab Is Effective in the Treatment of Refractory Post-Transplant Autoimmune Hemolytic Anemia: A Pediatric Case Report , 2016 .

[13]  Bie M. P. Verbist,et al.  Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma. , 2016, Blood.

[14]  R. Groen,et al.  Upregulation of CD38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumab , 2015, Leukemia.

[15]  G. Danet-Desnoyers,et al.  Anti-Leukemic Activity of Daratumumab in Acute Myeloid Leukemia Cells and Patient-Derived Xenografts , 2014 .

[16]  E. Thiel,et al.  Clinical and molecular characterization of early T-cell precursor leukemia: a high-risk subgroup in adult T-ALL with a high frequency of FLT3 mutations , 2012, Blood Cancer Journal.

[17]  S. Hunger,et al.  Reinduction platform for children with first marrow relapse of acute lymphoblastic Leukemia: A Children's Oncology Group Study[corrected]. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.